GlassScriptPhysician profile
Timothy A Crater
NPI 1508845876
$3,101.76
in general payments reported to CMS, 2019-2025
36 companies · $483 in 2025
The $483 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $762 · 2021: $59.69 · 2022: $234 · 2023: $439 · 2024: $433 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,355.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $767.35 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $370.55 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $327.36 | 2020-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $318.77 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $261.93 | 2020-2025 | Arexvy, Trelegy Ellipta |
| Pfizer INC. | $119.55 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $96.16 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.77 | 2024-2025 | |
| Axsome Therapeutics, INC. | $66.12 | 2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.56 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $57.06 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $43.01 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.06 | 2019-2020 | |
| Dexcom, INC. | $40.07 | 2023-2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $38.71 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $38.58 | 2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $31.90 | 2024 | Inspire |
| Allergan, INC. | $29.53 | 2020 | |
| Currax Pharmaceuticals LLC | $29.38 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.86 | 2020-2022 | |
| Lilly USA, LLC | $28.59 | 2019-2020 | |
| Ardelyx, INC. | $26.73 | 2025 | Ibsrela |
| Eisai INC. | $20.79 | 2020 | |
| Lundbeck LLC | $20.41 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $20.16 | 2023 | Rexulti |
| Abbott Laboratories | $19.45 | 2021 | |
| Nestle Healthcare Nutrition INC. | $18.61 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.97 | 2025 | Trintellix |
| Mylan Specialty L.P. | $17.54 | 2024 | Yupelri |
| Janssen Biotech, INC. | $16.67 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.32 | 2020 | |
| Amarin Pharma, INC. | $15.16 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.89 | 2022 | |
| Esperion Therapeutics, INC. | $14.19 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Crater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.